Evidence map›Paper›PMID 37158775›Full record

ArticleJournal of Korean medical science2023

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose.

Sung Hee Lim, Seong Hyeok Choi, Ji Youn Kim, Bora Kim, Han Jo Kim, Se Hyung Kim, Chan Kyu Kim, Seong Kyu Park, Jina Yun

Open access · goldAbstract read
In one paragraph

Article in Journal of Korean medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sung Hee Lim *Division of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0003-0845-9994
Seong Hyeok Choi *Division of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-1280-7798
Ji Youn Kim *Division of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-7605-801X
Bora KimDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-6836-4682
Han Jo KimDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Cheonan Hospital, Cheonan, Korea.ORCID https://orcid.org/0000-0002-5721-1728
Se Hyung KimDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-3426-1191
Chan Kyu KimDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-8002-5085
Seong Kyu ParkDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-3055-3621
Jina YunDivision of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea. 19983233@schmc.ac.kr.ORCID https://orcid.org/0000-0001-5897-8309
Bucheon University · KRSoonchunhyang University · KR

Funding

Soonchunhyang University 2023-0038
6 · The paper itself

Abstract

backgroundA fourth dose of vaccination is known to help reduce the severity and mortality rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The South Korean vaccination guidelines for the fourth dose do not include healthcare workers (HCWs) as priority candidates. We investigated the necessity of the fourth dose in South Korean HCWs based on an 8-month follow-up period after the third vaccination.

methodsChanges in the surrogate virus neutralization test (sVNT) inhibition (%) score were measured at one month, four months and eight months after the third vaccination. The sVNT values were analyzed between infected and uninfected groups, and their trajectories were compared.

resultsA total of 43 HCWs were enrolled in this study. In total, 28 cases (65.1%) were confirmed to be infected with SARS-CoV-2 (presumed omicron variant), and all had mild symptoms. Meanwhile, 22 cases (78.6%) were infected within four months of the third dose (median, 97.5 days). Eight months after the third dose, the SARS-CoV-2 (presumed omicron variant)-infected group showed significantly higher sVNT inhibition than that in the uninfected group (91.3% vs. 30.7%;

conclusionFor HCWs who had coronavirus disease 2019 infection after completing a third vaccination, a sufficient antibody response was maintained until eight months after the third dose. The recommendation of the fourth dose may not be prioritized in subjects with hybrid immunity.

Indexed as

COVID-19VaccinesBNT162 VaccineFollow-Up StudiesHealth PersonnelHumansSARS-CoV-2BNT162 VaccineVaccinesHybrid ImmunityNeutralizing AntibodyOmicronSARS-CoV-2

Identifiers

PMID37158775
PMCPMC10166699
OpenAlexW4366316464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.